Wellnex Reports 5.1% Revenue Growth and $4.5 Million FY26 Loss

Sharp Loss Reduction Highlights Strategic Turnaround

Wellnex Life Limited (ASX:WNX) has reported a marked improvement in its financial results for the year ended 30 June 2026, with revenue climbing 5.1% to $24.8 million and its net loss shrinking by over 70% to $4.5 million. This dramatic reduction from the prior year’s $15.6 million loss underscores the impact of a strategic turnaround program initiated during the year, which focused on cost discipline, operational simplification, and enhanced capital management.

The company’s gross margin edged up to 30.2%, slightly above the previous year’s 29%, reflecting better underlying performance across its portfolio. Importantly, Wellnex achieved positive operating cash flow in both the third and fourth quarters of FY26, a turnaround from a $3.1 million outflow in the first half to a $0.5 million inflow in the second half, signalling improving cash conversion and operational resilience.

Pain Away Brand Sale to Strengthen Balance Sheet

In a defining move to reinforce its financial footing, Wellnex has entered into a binding agreement to divest its flagship Pain Away brand to Mentholatum Australasia Pty Ltd for an upfront consideration of $19.8 million, plus an earn-out of up to $1.5 million subject to performance targets. The transaction, pending shareholder approval at a scheduled EGM on 8 September 2026, is expected to provide the company with the capital necessary to repay debt and bolster its balance sheet.

Pain Away accounted for approximately $13 million in sales during FY26 and maintained a strong position in Australia’s topical pain relief market, with expanded distribution including Priceline and major pharmacy wholesalers. The sale marks a strategic pivot away from consumer healthcare products towards contract manufacturing and licensing, areas where Wellnex aims to grow sustainably.

Governance Changes and Portfolio Rationalisation

FY26 also saw significant governance reshuffling, with the resignation of several executive directors including joint CEOs Zack Bozinovski and George Karafotias, and the appointment of Eric Jiang as Interim Executive Chair. The Board was streamlined from seven to four members, reflecting a leaner management structure aligned with the company’s turnaround goals.

Alongside the Pain Away divestment, Wellnex continued to rationalise its brand portfolio, discontinuing investment in underperforming brands such as Mr Bright and divesting the Wakey Wakey and Nighty Night brands. This disciplined focus aims to concentrate resources on higher-return activities and reduce working capital demands.

Operational Focus on Licensing and Manufacturing

Wellnex’s contract manufacturing and IP licensing operations remain a core component of its strategy. The company extended its licensing and supply agreement with Haleon UK Trading Services Limited for liquid softgel paracetamol products through to March 2027, underpinning its international revenue streams. The partnership with Chemist Warehouse on the Wagner Liquigesic analgesic range also provides exposure to the Australian OTC analgesics market.

Despite the improvements, the company’s net assets declined 33.7% to $7.5 million, and the auditor flagged a material uncertainty regarding going concern due to ongoing losses and cash outflows. However, the Pain Away sale and cost reduction initiatives are seen as mitigating factors that could restore financial stability.

Debt and Related Party Loan Extensions

Wellnex carries borrowings of $9.8 million, including a $5.3 million asset-based loan facility and $3.1 million in related party loans from former directors. Repayment terms for these loans have been extended in conjunction with the Pain Away sale process, with the company agreeing to pay finance charges for these extensions. The proceeds from the Pain Away divestment are earmarked to repay these debts, which will be a critical step in strengthening the company’s financial position.

The company’s focus on cost control and capital allocation remains firm, with management aiming to minimise reliance on external funding and drive sustainable growth in revenue and margins.